DorsaVi Ltd (ASX: DVL) Share Price and News

Mr Abl is a public company director with a background in law, corporate finance, and management consulting and has more than 20 years of entrepreneurial, business strategy, and investment experience. Gernot has worked with many early-stage businesses, across industries, to help commercialise, grow, and increase the value of the business for all stakeholders. Gernot is also on the board of and advises several medium and high-growth businesses, ranging from early-stage pre-revenue companies through to early-stage ASX-listed companies.

Mr Ronchi was a practicing physiotherapist both at an AFL club and in private practice. He has also been founding partner in two physiotherapy centers, the largest of these employing 28 staff (including 13 physiotherapists).

Mr Travers is currently the Director of Emerging Markets with Hong Kong-based web3 investment and incubation company Animoca Brands. Mr Travers was previously the CEO of Binance Australia from 2021 to mid-2023. Mr Travers has also been a Director and CEO of DigitalX Limited (ASX:DCC), He has spent his career in public markets, including as a Non-Executive Director for investment and technology companies on the NASDAQ and the TSX. In his professional career Mr Travers was also involved in several other technology related initiatives including: Championed the adoption of blockchain and the pathway for blockchain businesses as Director and Treasurer of Australias blockchain industry body. Provided technical, marketing and investor advisory services to multiple blockchain startups which went on to achieve unicorn status.

Dr Winlo has a leadership experience across the biotechnology, pharmaceutical and technology sectors. He is currently Chief Executive Officer. Dr Winlo also serves as a director and former CEO of Linear Clinical Research, a world-class provider of early and late-stage pharmaceutical trial facilities and management services. Prior to his role at Linear, Dr Winlo was based in Silicon Valley for five years as the Health Lead at Palantir Technologies (NYSE: PLTR).

Mr Agarwal has 18 years in the technology sector. Mr Agarwal is currently Product Management Director at Advanced Micro Devices (NASDAQ:AMD), where he has overseen management and product launch of the Ryzen Client Product line. Prior to AMD, Mr Agarwal held strategic roles at Qualcomm (NASDAQ:QCOM), including Director of Program Management and Senior Manager, driving the development of QCOMs Snapdragon platform.

-

-